# Assessment of drug-related migraine in a real-world large-scale database

## TL;DR

This study uses real-world data to identify drugs linked to an increased risk of causing migraines, highlighting specific medications and categories that may contribute to this condition.

## Contribution

The study provides a large-scale pharmacovigilance analysis identifying drugs and therapeutic classes associated with elevated migraine risk using FAERS data.

## Key findings

- 20,886 migraine-related adverse events were identified, mostly in females aged 45.7 years.
- 39 drugs showed significant migraine risk, with lorcaserin, tasimelteon, and botulinum toxin type A having the highest risk.
- High-risk drug categories included immunosuppressants, estrogens/progestogens, and sedative-hypnotics.

## Abstract

Drug-induced migraine represents a clinically significant yet under-investigated subtype of migraine. This study aims to evaluate the risk of drug-related migraine based on real-world data from the FDA Adverse Event Reporting System (FAERS).

A retrospective pharmacovigilance analysis was conducted using FAERS data from Q1 2004 to Q4 2024. Migraine cases were identified via standardized MedDRA (The Medical Dictionary for Regulatory Activities) terms. Only primary suspect drugs were included. Disproportionality analyses were performed using four algorithms: ROR, PRR, MGPS, and BCPNN. Drugs were classified by therapeutic indication and mechanism of action, and stratified by BCPNN values to assess risk levels.

A total of 20,886 migraine-related adverse events were identified, predominantly among females (77.4%) with a mean age of 45.7 years. Sixty-six drugs yielded positive signals, and after exclusion criteria, 39 remained for further analysis. The highest-risk agents included lorcaserin (BCPNN = 3.33), tasimelteon (3.20), and botulinum toxin type A (3.06). High-risk therapeutic classes included immunosuppressants, estrogens/progestogens, and sedative-hypnotics.

This large-scale analysis identifies key drug categories and compounds associated with an elevated risk of migraine, providing actionable insights for clinicians. Especially lorcaserin, tasimelteon, and botulinum toxin as potential risk factors for migraine. Given the public health burden of migraine, pharmacovigilance efforts should incorporate such findings to mitigate iatrogenic risks. Further prospective studies are warranted to establish causal mechanisms and optimize therapeutic decision-making.